Kite Pharma (KITE) Posts Q4 Loss of 85c/Share

Kite Pharma (NASDAQ: KITE) reported Q4 EPS of ($0.85), which may not compare with the analyst estimate of ($0.71). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• HSBC sees more upside in Intel stock on server CPU opportunity
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside